Repligen reported third-quarter 2026 revenue of $209.3 million, up 11% from $188.8 million a year earlier, and raised its full-year 2026 revenue guidance to $844 million-$852 million. The company swung to a GAAP loss of $0.68 per diluted share, driven by a $41.2 million intangible asset impairment charge, though adjusted EPS rose to $0.53 from $0.46.
Q3 revenue $209.3 million vs. $188.8 million a year earlier, up 11% as reported and 12.5% organic
GAAP loss per diluted share $0.68 vs. EPS of $0.26, including a $41.2 million intangible asset impairment charge
Adjusted diluted EPS $0.53 vs. $0.46; FY26 revenue guidance raised to $844 million-$852 million
BioLife Solutions acquisition closed October 6, 2026; cash and marketable securities $863 million at September 30, 2026
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Repligen's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$738.26M
+16.4%
$0.86
—
6.6%
FY2024
$634.44M
+0.3%
$-0.46
-173.0%
-4.0%
FY2023
$632.36M
-21.1%
$0.63
-80.6%
5.6%
FY2022
$801.54M
+19.5%
$3.24
+44.6%
23.2%
FY2021
$670.53M
+83.1%
$2.24
+101.8%
19.1%
Frequently asked questions
When is Repligen's next earnings date?
Repligen has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Repligen earn last quarter?
For the quarter ended Sep 2026, Repligen reported diluted EPS of $-0.68 (-361.5% year over year) on revenue of $209.31M (+10.9%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.